ABSTRACT
between host and microbe that define health are poorly resolved. Metagenomic clinical 27 studies clarify this definition by revealing gut microbial taxa and functions that stratify 28 healthy and diseased individuals. However, the typical single-disease focus of 29 microbiome studies limits insight into which microbiome features robustly associate with 30 health, indicate general deviations from health, or predict specific diseases. Additionally, 31 the focus on taxonomy may limit our understanding of how the microbiome relates to 32 health given observations that different taxonomic members can fulfill similar functional 33 roles. To improve our understanding of the association between the gut microbiome and 34 health, we integrated about 2,000 gut metagenomes obtained from eight clinical studies 35 in a statistical meta-analysis. We identify characteristics of the gut microbiome that 36 associate generally with disease, including functional alpha-diversity, beta-diversity, and 37 beta-dispersion. Moreover, we resolve microbiome modules that stratify diseased 38 individuals from controls in a manner independent of study-specific effects. Many of the 39 differentially abundant functions overlap multiple diseases suggesting a role in host 40 health, while others are specific to a single disease and may associate with disease-41 specific etiologies. Our results clarify potential microbiome-mediated mechanisms of 42 disease and reveal features of the microbiome that may be useful for the development of 43 microbiome-based diagnostics. Ultimately, our study clarifies the definition of a healthy 44 microbiome and how perturbations to it associate with disease. 45
INTRODUCTION 47
Mounting evidence implicates the gut microbiome as a critical component of 48 human health. For example, research demonstrates that the gut microbiome contributes 49 to immunity, nutrition, and behavior [1, 2] . Accordingly, gut microbiomes of diseased 50 individuals tend to harbor different taxa and encode different genes than those of healthy 51 individuals [3] . These observations motivate the hypothesis that human health depends, 52 in part, upon the taxonomic composition and biological functions executed by the gut 53 microbiome. Therefore, researchers have sought to identify the properties of the human 54 gut microbiome that signify health and disease. Such signatures are valuable to resolve 55 because they provide important context for the development of disease diagnostics, 56 clarify disease etiology, and generate insight into how microbiomes should be amended 57 to restore health. 58
An extensive array of prior investigations focused on defining the characteristics 59 of the gut microbiome that signify health or disease. One such effort was led by the 60 Human Microbiome Project, which defined the structure and function of the gut 61 microbiome that associates with clinically healthy, urban, North Americans [4] . Other 62 investigations used clinical 16S data to determine how the structure of the gut microbiome 63 of diseased individuals differs from that of healthy individuals. More recently, a smaller 64 set of investigations used shotgun metagenomes to resolve how both the structure and 65 functional diversity of the gut microbiome associates with disease [5] [6] [7] [8] [9] [10] [11] [12] . However, almost 66 all of these investigations have focused on a single disease population and a matching 67
control. Very few studies integrate data across multiple populations, incorporate data from 68 other studies, or compare patterns across various disease types. Consequently, it is 69 unclear which associations are robust to population or study effects. Moreover, we 70 possess limited insight into which associations are specific to a disease-type versus those 71 that are common to myriad diseases. These limitations hinder our ability to develop robust 72 clinical diagnostics from microbiome data and obscure our understanding of the potential 73 mechanisms through which the microbiome contributes to a specific disease or health in 74
general. 75
Integrating data across investigations through a meta-analysis is a proven tactic 76 for overcoming these limitations [13] [14] [15] . Though their application in microbiome science 77 remains limited, meta-analyses provide important clarity in microbiome research. For 78 example, meta-analysis of 16S-based investigations surrounding human obesity revealed 79 that originally reported associations between the taxonomic composition of the gut 80 microbiome and obesity were inconsistent across studies [16] and appear to only manifest 81 weak statistical effects [17] . Additionally, a meta-analysis of 16S data quantified the 82 microbiome's taxonomic association with disease across several populations that span a 83 variety of diseases revealing that some microbiome changes are disease specific while 84 others are associated with multiple diseases [14] . The application of meta-analyses to 85 shotgun metagenomic data is even more restricted, in part due to the limited amount of 86 clinical metagenomic data currently available. One study integrated metagenomes to 87 assess the predictive capacity of the taxonomic profile of the microbiome for several 88 diseases finding that integrating multiple datasets improved prediction capabilities [15] . 89
These studies highlight the importance of data integration in contributing to our 90 understanding of the role of the microbiome in health and disease. 91
While these studies have proven insightful, their focus on taxonomy may limit our 92 understanding of how the microbiome relates to health. Metagenomes afford insight into 93 the types of genes, and consequent biological pathways, encoded by the microbiome. 94
Resolving the association between microbiome functions and health may prove critical to 95 determining the mechanisms through which the microbiome promotes health or 96 contributes to diseases and may reveal robust indicators of disease given observations 97 of functional redundancy where different microbes can fulfill the same functional 98 roles [18, 19] . However, the application of meta-analyses to the functional diversity of the 99 gut microbiome is limited to a single study of Type 2 diabetes which revealed gene 100 families encoded in the microbiome that consistently associate with diseases across two 101 continents [20] . The integration of metagenomic datasets in this study revealed the 102 confounding contribution of anti-diabetic medicine to the results, emphasizing the need 103 to consider additional factors, such as medication, in assessments of the gut 104 microbiome's relationship to health and disease. 105
Here, we describe the first meta-analysis of microbiome gene functions that span 106 multiple disease-types and populations. We integrated ~2,000 publically available 107 metagenomes that span 8 studies and 7 diseases through a regression-based statistical 108 framework. Our study (1) reveals that functional diversity indicates disease, but usually 109 with weak effect, (2) resolves microbiome functions that associate with multiple diseases, 110
suggesting that these functions may be important to host health in general, (3) identifies 111
functions that indicate specific diseases, which could aid the development of diagnostics, 112 and (4) quantifies the large effect of study-specific parameters on the functional diversity 113 of the gut microbiome. 114
METHODS 116

Dataset 117
Our analysis relied on public metagenomes, which we obtained from the NCBI 118 SRA and identified using SRAdb [21] . Specifically, we downloaded 10 Tbp of 119 metagenomic sequence data from 1,979 subjects across 8 studies and 5 countries. 120
Included in the dataset are non-diseased controls as well as subjects with one or more of 121 
Data processing and annotation 126
We applied the standard MetaQuery quality control steps to quality filter all data 127 and remove sequencing runs that failed quality control. Specifically, we deemed runs to 128 be of sufficient quality if all of the following conditions were met: > 70% of reads mapped 129 to the reference database, the mean read length was > 50-bp, the mean GC-content was 130 > 40%, the mean read quality was > 21, and > 98% of reads were free of adaptor 131 For each disease, we identified a set of subjects that represented disease-afflicted 143 individuals (i.e. cases) and a set of subjects that represented healthy individuals (i.e. 144 controls) (Table 1) . Specifically, we deemed subjects that were clearly determined to have 145 the disease of interest and none of the other diseases in the available metadata to be 146 case subjects (i.e., no co-morbidity). Control populations alternatively consisted of 147 individuals who were explicitly determined through clinical screening not to have the 148 disease of interest, irrespective of the specific study from which the metagenome was 149 generated. Designation of cases and controls relied on the metadata provided by the 150 initial study. It is possible that a subject could have an undetected disease that was not 151 screened for in a given a study. Rheumatoid arthritis subjects that manifested low disease 152 severity or remission were excluded from these analyses. Subjects whose metagenomes 153 were sequenced multiple times, either as technical or biological replicates, were only 154 represented by the first metagenome sample that the study authors generated. Ultimately, 155 1,473 samples passed these analytical filters and were included in the downstream 156
analyses. 157 158
Alpha and beta-diversity 159
The vegan package in R was used for alpha and beta-diversity quantification. module, the genomic copy number was used as the response variable and disease 178 status as the predictor. For disease phenotypes with data from multiple studies, the 179 source study was also included as a covariate in the models to account for study 180 effects. False discovery rate correction (stats::p.adjust) was used to adjust for multiple 181 tests and a cutoff of FDR < 0.2 was used to identify indicators for each disease. 182
183
RESULTS
184
Gut metagenome functional diversity associates with disease. 185
We integrated publically available gut metagenomic data from 1,473 patients spanning 186 seven diseases and eight studies to discern how the functional diversity of the gut 187 microbiome associates with disease. In particular, we investigated how protein family 188 richness, the functional composition of the gut microbiome, and gut microbiome functional 189 beta-dispersion relate to disease. These analyses clarify the diagnostic potential of gut 190 microbiome functional diversity and point to putative microbiome-mediated disease 191
mechanisms. 192
We observe a decrease in the number of KEGG Orthology Groups encoded in the gut Crohn's disease, ulcerative colitis, obesity, and type II diabetes (Adonis p < 0.02; Figure  211 2). However, the magnitude of these differences varies across diseases, ranging from 212 relatively strong effects in Crohn's disease (partial R 2 = 13%) to weak effects in obesity 213
(partial R 2 = 2%). Moreover, colorectal cancer and rheumatoid arthritis exhibit no 214 detectable differences in functional beta-diversity between cases and controls. Similar to 215 our richness analysis, these results indicate that the gut microbiome tends to encode 216 different kinds of functions in association with disease, but that the differentiation is 217 relatively modest and may challenge diagnosis. 218
Beta-dispersion measures the compositional variation of the microbiome among a 219 group of individuals, and prior work has linked disease to an increase in taxonomic beta-220 dispersion [29] . We similarly measured whether gut microbiome functional beta-221 dispersion varies between healthy and diseased populations. We observe an increase in 222 functional beta-dispersion among individuals diagnosed with colorectal cancer, Crohn's 223 disease, and liver cirrhosis (p < 0.05; Figure 2 ). Individuals afflicted with obesity display 224 a reduced beta-dispersion relative to their controls, but these results could be confounded 225 by study effects. The remaining diseases presented no detectable difference in functional 226 beta-dispersion. As observed with functional richness and beta-diversity, the effect size 227 of beta-dispersion varies across diseases, but for some diseases appears to be relatively 228 substantial. These results indicate that several diseases associate with an increased 229 variation in the functional composition of the gut microbiome, possibly because there are 230 relatively few functional assemblages that associate with control populations and many 231 functional assemblages linked to disease. 232 233
Metagenome modules indicate disease and clarify mechanisms of health. 234
We next examined whether specific microbiome functions associate with disease. 235
To reduce data dimensionality, we collapsed KEGG Orthology Groups into modules. We 236 then used compound Poisson linear regression to model the relationship between health 237 state and the average genomic copy number of KEGG modules. These methods have 238 been applied in prior work [26] and allow for robust modeling of sparse but otherwise 239 continuous data. Moreover, they afford the ability to account for potential study effects 240 through the inclusion of additional covariates. Using these models, we defined indicators 241 of a disease to be those modules whose average genomic copy number in the 242 metagenome significantly associates with the health status of the host. 243
We find that of the 521 modules defined across our data set, 484 indicated disease in 244 Table 2 ). These results suggest that different diseases may manifest 253 similar mechanisms of association with the gut microbiome (e.g., inflammation), or that 254 microbiome modules may play varying roles in determining how the microbiome 255 associates with different diseases. 256
We reasoned that the high frequency of modules that indicate multiple diseases may 257 reflect the existence of modules that indicate any disease. While no modules stratified 258 cases and controls across all seven diseases in our analysis, 33 modules indicated at 259 least four but no more than five distinct diseases, and each disease is indicated by at 260 least six of these 33 common disease indicators. Some diseases are indicated by a large 261 proportion of these modules, including Crohn's disease (97%), liver cirrhosis (88%), type 262 II diabetes (73%), and obesity (79%). Conversely, rheumatoid arthritis (18%), colorectal 263 cancer (33%), and ulcerative colitis (18%) are indicated by relatively few modules. That 264 said, these modules can constitute a substantial fraction of the total indicators discovered 265 for this latter set of diseases, as evidenced by the fact that 46% of the ulcerative colitis 266 modules are among this common set. Despite the frequent number of diseases indicated 267 by these modules, they do not always indicate diseases through consistent signatures. 268 Seven independent studies generated shotgun metagenomes for subjects with 306 (n=211) and without (n=684) obesity. We integrated data across these studies by adding 307 a study covariate to our regression models to resolve indicators of disease that are robust 308 to study effects. We find that the source study accounts for approximately 25% of the 309 variation in functional composition between obese individuals relative to controls, while 310 disease status accounts for only 0.7%. Despite the contribution of study effects, we were 311 able to detect 144 KEGG modules that indicate disease in the microbiome of subjects 312 with obesity. This set of obesity indicators includes thiamin biosynthesis (M00127), EHEC 313 pathogenicity signature (M00363), and acetate production (M00618, M00597, M00377). 314
315
DISCUSSION 316
Our integrative analysis reveals the functional attributes of the gut metagenome 317 that relate to human health and disease. We show that for several diseases, healthy 318 microbiomes encode higher protein family richness, significantly different functional 319 compositions, and increased constraint on the variation in that composition as compared 320 to disease-associated microbiomes. However, effect sizes are frequently weak and not 321 all diseases manifest these trends. Moreover, we identify specific functional modules that 322 associate broadly with disease and, therefore, may be important to maintaining host 323 health. Additionally, we resolve disease-specific markers that help clarify disease etiology 324 and may serve as potential diagnostic biomarkers. Ultimately, the microbiome functions 325 that we identify as being enriched in healthy individuals and disrupted in diseased 326 individuals may illuminate how the microbiome contributes to host health. 327
We find that disease tends to associate with a reduction in the number of distinct 328 protein families encoded in the microbiome. One potential explanation for this 329 observation is that disease results in an altered gut environment that places selective 330 pressures on microbes to possess specific functions. The microbes that carry these 331 functions may also have similarities in the remainder of their genomes, thereby reducing 332 the overall functional diversity in the microbiome. Additional support for this potential 333 explanation comes in the form of our observation that diseases with arguably more 334 severe intestinal symptoms (i.e. Crohn's disease) display the largest deficit in richness 335 while diseases with subtle intestinal symptoms (i.e. rheumatoid arthritis) have little 336 difference in protein family richness between cases and controls. Our observation of 337 decreased functional richness in diseased populations is consistent with reports that 338 taxonomic diversity tends to be reduced in the microbiome of diseased populations 339 relative to controls [11, 27, 28] . These reports prompted the disappearing microbiota 340 hypothesis [31], which suggests that generational loss of ancestral members of the gut 341 microbiota has adverse repercussions on host health. Based on our results, this 342 hypothesis could be extended to include protein family richness, where loss of ancestral 343 functions carried out by the gut microbiota may result in host disease. 344
Our integration of metagenomic data also enabled comparison of the differences 345 in the gut microbiome's functional composition across a variety of diseases. We find that 346 while the microbiome's functional composition associates with host health, the strength 347 of the association substantially varies by disease and is generally relatively small. This 348 suggests that disease is not defined by a substantial restructuring of the functional 349 composition of the gut microbiome. Rather, if the microbiome contributes to diseases it 350 does so through changes in the abundance of specific protein families, which may be 351 different in each diseased subject. Consequently, health is not necessarily defined by 352 the sum total of the functional capacity of the microbiome. Furthermore, analysis of the 353 microbiome's functional beta-dispersion reveals that most diseases have increased 354
inter-sample variation in the microbiomes of the case populations relative to the 355 microbiomes of the control populations. This pattern of increased dispersion in disease-356 associated microbiomes was previously observed in studies of taxonomic diversity and 357 dubbed the Anna Karenina principle (AKP) [29] . AKP hypothesizes that certain 358 stressors elicit stochastic effects on the taxonomic composition of the microbiome to 359 yield increased variation in the stressed group relative to control group. Our beta-360 dispersion analysis shows that AKP effects are also found in the functional profiles of 361 the gut microbiome in diseased hosts. This observation indicates that the increased 362 dispersion observed in the taxonomic analysis of diseased microbiomes is unlikely to be 363 the result of redundant functional compositions across communities, since if that was 364 the case we would expect to find little to no increase in dispersion in the functional 365 profiles. That said, our observation does not preclude the possibility that different taxa 366 encode a small set of redundant proteins that associate with the disease state. 367 Additionally, our finding that there tends to be lower functional dispersion among healthy 368 individuals indicates that there may exist greater constraints on how the microbiome 369 operates among healthy individuals. 370
Our robust and integrative modeling approach reveals specific associations 371 between microbiome function and health by identifying commonly perturbed functions that 372 may be impactful to host health. Interestingly, most of the common indicators (i.e., 373 indicators of four or more diseases) are increased in abundance in the microbiomes of 374 diseased subjects relative to the microbiomes of control subjects. This suggests that the 375 shared disease associations with the microbiome may be due to the elevated presence 376 of some microbiome functions rather than their loss in the microbiome. For example, 377 subjects with colorectal cancer, liver cirrhosis, Crohn's disease, and obesity have 378 have low iron levels due to reduced iron absorption and iron loss through intestinal 388 bleeding [33] . Patients with obesity and liver cirrhosis also tend to have a higher risk for 389 low iron levels [34, 35] , while subjects with type II diabetes tend to have high iron levels 390 [36] . Differing abundance of iron transporters in the gut microbiome is a consistent 391 indicator for disease, but the relationship to etiology seems to differ by disease. Another 392 common indicator is acetate production (M00377 and M00618), which is increased in the 393 gut microbiome of subjects with rheumatoid arthritis, Crohn's disease, obesity, and type 394 II diabetes. Production of short chain fatty acids (SCFAs), particularly acetate and 395 butyrate, are thought to act as signaling molecules between the gut microbiome and host 396 and may play a role in host metabolism [37] . The finding that increased abundance of 397 modules for acetate production is consistent across diseases supports prior work linking 398 microbe-produced SCFAs to disease. Through integration of data spanning various host 399 health states, we gain a clearer picture of how the microbiome operates in relation to host 400 health and what constitutes a healthy microbiome. It is possible that there are reasons 401 we don't detect differences in these common modules for more diseases, such as 402 insufficient sample size or inability to control for unknown sources of variation that mask 403 meaningful differences. The lack of universal markers could be due to fundamental 404 differences in the diseases being examined. Additionally, the indicators identified require 405 further investigation to determine the association with disease as some indicators may be 406 a response to disease while others may play a role in disease development or 407
progression. 408
Another benefit to the integration of data from distinct diseases is the ability to 409 disentangle disease-specific from common indicators, which can be used to clarify the 410 etiology of specific diseases and potentially act as biomarkers for disease diagnosis. For 411 example, rheumatoid arthritis cases have increased abundance of a module for methane 412 production (M00618) relative to controls. Increased abundance of methane producing 413 microorganisms and elevated levels of methane were reported in patients with multiple 414 sclerosis, an autoimmune disease that affects the central nervous system [38] . The 415 identification of this module as a unique indicator for rheumatoid arthritis here and similar 416 findings in a related disease suggests that methane production by gut microbiota may 417 associate with autoimmune conditions. Additionally, modules for degradation of 418 glycosaminoglycans (GAGs) (M00076, M00077, M00078, M00079) are uniquely elevated 419 in subjects with Crohn's disease. Disruption of GAGs in Crohn's disease subjects has 420 been reported previously [39] and may be due to increased degradation by gut microbiota. 421
The observation that this increased abundance of GAG degradation modules is unique 422 to Crohn's disease subjects suggests this could serve as a diagnostic indicator and may 423 be a target for therapeutics to restore intestinal integrity. 424
While these disease-specific indicators suggest that the microbiome could be useful 425 in diagnostics, a more accurate and reliable approach may be gained by moving away 426 from categorical assessments of health and towards quantitative measures of health. 427
Consideration of disease progression as well as additional physiological covariates may 428 also improve the diagnostic potential of the gut microbiome. For example, these 429 personalized properties of disease may explain the relatively high variation in microbiome 430 composition amongst diseased individuals. Moreover, our results demonstrate that the 431 development of microbiome-based diagnostics of disease must consider the sensitivity of 432 the microbiome to study effects. Indeed, for the two diseases for which we could quantify 433 study effects, we found that these effects are much larger than the effect of disease on 434 the microbiome. This study-associated variance could come from a variety of sources, 435 including subject recruitment, sample collection and processing, and sequencing 436 technology. Regardless, future efforts to develop microbiome-based diagnostics should 437 similarly strive to integrate data across diverse studies to resolve robust indicators of 438
disease. 439
The observed indicators of disease also clarify the potential role of the microbiome 440 in various diseases. By focusing on what the microbiome is capable of doing, rather than 441 which taxa are present, and how this functional capacity associates with health, we can 442 develop testable hypotheses about how the microbiome may mediate health and disease. 443 Collectively, our analysis discerns how the gut microbiome's functional capacity 456 relates to host health. Through integration of data spanning multiple health states, we 457 observe broad patterns of microbiome changes in disease that clarify how the gut 458 microbiome contributes to health. For example, the metabolic modules that are commonly 459 perturbed during disease may reflect mechanisms through which the gut microbiome 460 interacts with physiology to promote health. Future studies should explicitly test whether 461 these microbiome functions are critical to maintaining health. Moreover, disease 462 associates with a personalized alteration in the functional composition in the microbiome, 463
as indicated by our beta-diversity and -dispersion analyses. This result indicates that 464 microbiome-based therapies may need to consider patient-specific parameters to ensure 465 efficacy. Additionally, we uncover disease-specific indicators that not only serve as 466 diagnostic leads, but also clarify potential microbiome-mediated etiologies of disease. 467
Future studies should similarly seek to test the effects of these microbiome functions on 468 health. Ultimately, integrative data analysis can expand our understanding of the role of 469 the microbiome in maintaining health, but requires more comprehensive patient data, 470 standardized methodologies, and extended patient populations to maximize its utility. 
